This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RAS Tarmogen
Description: The GI-4000 series is a new class of targeted immunotherapy products, called Tarmogen, being developed for the treatment of a number of different cancers. This series was developed using GlobeImmune's patented, yeast-based immunotherapy platform and targets a protein known as Ras that is mutated in a number of different types of tumors. The GI-4000 series consists of three products (GI-4014, GI-4015, and GI-4016) directed to five specific mutations in the Ras protein.
To create a new Tarmogen, DNA encoding target protein antigens are engineered into a yeast expression plasmid. The encoded antigens are markers of diseased cells and can be conserved viral proteins, mutated proteins unique to cancer cells, or proteins over-expressed in cancer. The heat-inactivated yeast, with the target protein inside, is the final Tarmogen product. Tarmogens are capable of stimulating the immune system to produce a highly specific and potent T cell response against the diseased cell, which contains the target antigens, with little or no impact on normal cells.
GlobeImmune and Celgene
In May 2009, GlobeImmune and Celgene announced a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on targeted molecular immunotherapy for the treatment of cancer. Under the terms of the agreement, GlobeImmune will receive a $40 million upfront payment from Celgene, which includes an equity investment in GlobeImmune. In return, GlobeImmune is granting Celgene an exclusive option to all oncology programs, including GI-4000 as well as all of GlobeImmunes other oncology product candidates on a program by program basis. GlobeImmune will conduct the early development of the product candidates through certain pre-defined endpoints. Celgene will have the option to obtain an exclusive worldwide license to develop and commercialize these unique immunotherapy product candidates. GlobeImmune is eligible to receive over $500 million in development and regulatory milestones,...See full deal structure in Biomedtracker
Additional information available to subscribers only: